Abstract: A dispenser for dispensing a flowable product from a container has a pump module mounted on the container at an opening thereof. The pump module includes a pump body, which defines a pump chamber and a pump chamber inlet for product to flow from the container interior into the pump chamber. A pump actuator is operable in a pumping stroke relative to the pump body to vary the volume of the pump chamber and dispense the product. The pump includes a movable body portion which is operable in a displacement stroke into the container. The movable portion has a displacement body with a product-engaging face directed onto an interior product space of the container upstream of the pump chamber inlet, to assist priming. Below this a disrupter member, a grid of narrow bars, projects to penetrate the product.

Abstract: A dispenser for dispensing a flowable product from a container has a pump module mounted on the container at an opening thereof. The pump module includes a pump body, which defines a pump chamber and a pump chamber inlet for product to flow from the container interior into the pump chamber. A pump actuator is operable in a pumping stroke relative to the pump body to vary the volume of the pump chamber and dispense the product. The pump includes a movable body portion which is operable in a displacement stroke into the container. The movable portion has a displacement body with a product-engaging face directed onto an interior product space of the container upstream of the pump chamber inlet, to assist priming. Below this a disrupter member, a grid of narrow bars, projects to penetrate the product.

Abstract: The present invention relates to an isolated naturally-occurring soluble truncated IL-23R? protein, which is a translated protein resulting from a mRNA splice variant of IL-23R?. The soluble IL-23R? proteins (e.g., ?9 and ?8,9) represents a novel soluble IL-23R? protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that ?9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23R? protein. More importantly, the present invention provides an utility application of the ?9 and ?8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, ?9 and ?8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of ?9 and ?8,9 in treating a human patient inflicted with Crohn's disease.

Abstract: Systems and methods for configuring, identifying, and selecting a desired display device of one or more display devices for multimedia output are provided. In one embodiment, a spatial orientation, display device identifier, and one or more connectivity identifiers are associated with each of one or more display devices. The associated data for each of the one or more display devices is stored in as configuration data in a configuration database for subsequent use in selecting a desired display device.

Abstract: An interactive and custom support kiosk is disclosed. In one embodiment, a kiosk is provided including a user attribute identification system and a region-specific linkage. The user attribute identification system may be a user language identification system where the user's preferred language may be detected. With detection of a user's preferred language, the kiosk may display a language-customized display with customized features based on the identified language. In some embodiments, the customized features may include a language-based experience format similar to a user's experience which would be expected in the user's home geography. In some examples, a second level of interaction may be provided wherein the user may be connected to a region-specific operator. The operator may provide immediate live help or assistance through the kiosk. In addition, security controls may be provided with the interactive language and custom support kiosk.

Abstract: The present invention relates to cell-based assays involving HER2. The assays use assay cells that are transfected with cassettes containing the HER2 gene of interest and measure the effect of mutations on the activity of HER2, and on their response to inhibitors.

Abstract: The present invention relates to cell-based assays involving HER2. The assays use assay cells that are transfected with cassettes containing the HER2 gene of interest and measure the effect of mutations on the activity of HER2, and on their response to inhibitors.

Abstract: The present invention relates to cell-based assays involving HER2. The assays use assay cells that are transfected with cassettes containing the HER2 gene of interest and measure the effect of mutations on the activity of HER2, and on their response to inhibitors.

Abstract: The present invention relates to cell-based assays involving the estrogen receptor and/or aromatase. The assays use assay cells that are transfected with linear cassettes containing the ESR1 or the CYP19A1 gene of interest and measure the effect of mutations on the activity of the estrogen receptor and/or aromatase, and on their response to inhibitors.

Abstract: Managing data stored in a Data Storage Device (DSD) including a volatile memory and a non-volatile memory including a circular buffer. Metadata stored in the volatile memory is logically divided into blocks of metadata. At least one changed block of metadata is identified that has changed during operation of the DSD and the at least one changed block of metadata is stored in the circular buffer of the non-volatile memory.

Abstract: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23R? gene. Exon 9 skipping of the IL23R? gene ultimately causes specific induction of a novel soluble truncated IL-23R? (?9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a ?9 protein which inhibits IL-23R-mediated cell signaling. More particularly, ?9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease.

Abstract: A dispenser for dispensing a flowable product from a container has a pump module mounted on the container at an opening thereof. The pump module includes a pump body, which defines a pump chamber and a pump chamber inlet for product to flow from the container interior into the pump chamber. A pump actuator is operable in a pumping stroke relative to the pump body to vary the volume of the pump chamber and dispense the product. The pump includes a movable body portion which is operable in a displacement stroke into the container. The movable portion has a displacement body with a product-engaging face directed onto an interior product space of the container upstream of the pump chamber inlet, to assist priming. Below this a disrupter member, a grid of narrow bars, projects to penetrate the product.

Abstract: Systems and methods are provided for automatically recommending real-world actions and performing the same. The real-world action includes at least one of a scheduling action and a purchasing action. The method includes: obtaining data about a user; obtaining data about a partner organization; processing the data about the user and the partner organization to recommend the real-world action and to generate a tolerance rule; when the real-world action is within the tolerance rule, automatically performing the real-world action for the user and in collaboration with the partner organization; and when the real-world action is not within the tolerance rule, providing a notification to the user recommending the real-world action be performed.

Abstract: The present invention relates to novel linear and cyclic polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides (linear or cyclic), and use of same in inhibiting cell functions including production of IL-22 and IL-17F from immune cells as well as in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease, ulcerative colitis and multiple sclerosis.

Abstract: A naturally-occurring soluble truncated IL-23R? protein (i.e., ?9 IL-23R?) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23R? protein. More particularly, antibody-sandwich ELISA method and kits for ?9 IL-23R? as an antigen were developed to detect ?9 IL-23R? levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma.

Abstract: A naturally-occurring soluble truncated IL-23R? protein (i.e., ?9 IL-23R?) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23R? protein. More particularly, antibody-sandwich ELISA method and kits for ?9 IL-23R? as an antigen were developed to detect ?9 IL-23R? levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma.

Abstract: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23R? gene. Exon 9 skipping of the IL23R? gene ultimately causes specific induction of a novel soluble truncated IL-23R? (?9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a ?9 protein which inhibits IL-23R-mediated cell signaling. More particularly, ?9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease.

Abstract: Systems and methods for configuring, identifying, and selecting a desired display device of one or more display devices for multimedia output are provided. In one embodiment, a spatial orientation, display device identifier, and one or more connectivity identifiers are associated with each of one or more display devices. The associated data for each of the one or more display devices is stored in as configuration data in a configuration database for subsequent use in selecting a desired display device.

Abstract: The present invention relates to novel linear and cyclic polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides (linear or cyclic), and use of same in inhibiting cell functions including production of IL-22 and IL-17F from immune cells as well as in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease, ulcerative colitis and multiple sclerosis.